Profile data is unavailable for this security.
About the company
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
- Revenue in USD (TTM)0.00
- Net income in USD-62.52m
- Incorporated2021
- Employees30.00
- LocationZura Bio Ltd4225 Executive Square, Suite - 600SAN DIEGO 92037United StatesUSA
- Phone+1 (858) 247-0520
- Websitehttps://zurabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 520.40m | 72.00 | -- | 3.24 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -236.30m | 527.34m | 95.00 | -- | 3.92 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -223.12m | 539.59m | 202.00 | -- | 1.94 | -- | -- | -2.01 | -2.01 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -52.00 | -42.96 | -56.68 | -46.18 | -- | -- | -- | -- | -- | -- | 0.0713 | -- | -- | -- | 13.77 | -- | -56.75 | -- |
| Larimar Therapeutics Inc | 0.00 | -132.00m | 541.78m | 65.00 | -- | 3.22 | -- | -- | -1.93 | -1.93 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -64.96 | -45.05 | -76.53 | -50.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -118.15 | -- | -7.58 | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 560.36m | 41.00 | -- | 2.48 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -67.45m | 582.74m | 55.00 | -- | 2.92 | -- | -- | -1.19 | -1.19 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -28.49 | -18.88 | -29.66 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -62.52m | 582.83m | 30.00 | -- | 4.06 | -- | -- | -0.6686 | -0.6686 | 0.00 | 1.66 | 0.00 | -- | -- | 0.00 | -39.10 | -- | -49.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.45 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -314.85m | 591.22m | 479.00 | -- | 2.71 | -- | -- | -3.44 | -3.44 | 0.00 | 2.64 | 0.00 | -- | -- | 0.00 | -67.19 | -33.04 | -75.03 | -35.07 | -- | -- | -- | -- | -- | -- | 0.2565 | -- | -- | -- | -14.60 | -- | 0.4456 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 595.53m | 226.00 | -- | 1.88 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Perspective Therapeutics Inc | 1.08m | -106.31m | 609.44m | 138.00 | -- | 1.64 | -- | 566.92 | -1.46 | -1.46 | 0.0147 | 3.26 | 0.0031 | -- | 5.43 | 7,789.86 | -31.00 | -- | -33.37 | -- | -- | -- | -9,889.68 | -- | -- | -- | 0.0067 | -- | 1.39 | -- | -109.13 | -- | -- | -- |
| MeiraGTx Holdings PLC | 27.42m | -168.69m | 610.12m | 409.00 | -- | -- | -- | 22.25 | -2.11 | -2.11 | 0.343 | -0.5039 | 0.1121 | -- | 9.01 | 71,960.63 | -69.00 | -30.69 | -121.96 | -38.41 | 41.01 | -- | -615.27 | -428.39 | 0.2235 | -36.10 | 2.21 | -- | 137.42 | 20.15 | -75.89 | -- | -11.21 | -- |
| YD Bio Ltd | -100.00bn | -100.00bn | 613.18m | 5.00 | -- | 120.51 | -- | -- | -- | -- | -- | 0.0722 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.36 | -- | 0.0124 | -- | 45.76 | -- | -10,509.73 | -- | -- | -- |
| Ocugen Inc | 5.37m | -64.02m | 636.10m | 95.00 | -- | 171.50 | -- | 118.46 | -0.2167 | -0.2167 | 0.0182 | 0.0113 | 0.0899 | -- | -- | 56,526.32 | -107.12 | -79.82 | -153.51 | -95.76 | -- | -- | -1,192.18 | -2,251.08 | -- | -19.41 | 0.8894 | -- | -32.82 | -- | 14.31 | -- | 158.28 | -- |
| Alto Neuroscience Inc | 0.00 | -62.26m | 640.90m | 76.00 | -- | 5.02 | -- | -- | -2.31 | -2.31 | 0.00 | 4.11 | 0.00 | -- | -- | 0.00 | -36.77 | -- | -39.46 | -- | -- | -- | -- | -- | -- | -- | 0.1675 | -- | -- | -- | -69.21 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Athanor Capital LPas of 23 Jan 2026 | 11.58m | 17.81% |
| Suvretta Capital Management LLCas of 31 Dec 2025 | 5.57m | 8.56% |
| JPMorgan Securities LLC (Investment Management)as of 31 Dec 2025 | 4.47m | 6.88% |
| Great Point Partners LLCas of 31 Dec 2025 | 3.82m | 5.87% |
| Braidwell LPas of 31 Dec 2025 | 3.18m | 4.89% |
| Adage Capital Management LPas of 31 Dec 2025 | 2.75m | 4.23% |
| Affinity Asset Advisors LLCas of 31 Dec 2025 | 1.81m | 2.79% |
| Armistice Capital LLCas of 31 Dec 2025 | 1.56m | 2.40% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 1.50m | 2.31% |
| Millennium Management LLCas of 31 Dec 2025 | 1.03m | 1.59% |
